Ann Stem Cell Res Ther | Volume 2, Issue 2 | Research Article | Open Access
Padin Iruegas Me1*, Martinez Lago N2, Alba Losada J3, Garcia Caballero T4 and Lopez Lopez R2
1Department of Functional Biology and Health Sciences, University of Vigo, Spain
2Department of Medical Oncology, IDIS University Clinical Hospital, Spain
3Department of Medical Oncology, Polusa Policlinic Lucense, Spain
4Department of Pathology, University of Santiago de Compostela, Spain
*Correspondance to: Padin Iruegas Me
Fulltext PDFBackground: Pancreatic adenocarcinoma is one of the most aggressive solid neoplasms. Evidence exists for interactions between pancreatic cancer cells and stromal fibroblasts that affect the invasive phenotype of pancreatic cancer. Secreted Protein Acidic and Rich Cysteine (SPARC) is a protein involved in cell matrix interactions, and is highly expressed in a wide range of human malignant neoplasms. SPARC could play a role in tumor progression at the site of interface between neoplastic cells and the surrounding host cells.
Methods: We collected cases with diagnose of pancreatic infiltrating ductal adenocarcinoma. Samples were staining with anti-SPARC probe and listed in 3 categories depending on the staining intensity: negative or weak intensity (0-1+), moderate (2+) and high (3+).
Results: Results indicated that from all the variants, only SPARC high expression could be a prognostic factor. Patients with strong positivity for SPARC had a median survival of 11.9 months compared with 16.7 months for those which SPARC expression was moderate, weak or absent.
Conclusion: In this study, we demonstrated that stromal SPARC expression could be a potent marker of poor prognosis, independent of common clinical parameters.
Pancreas; Adenocarcinoma; SPARC
Padin Iruegas Me, Martinez Lago N, Alba Losada J, Garcia Caballero T, Lopez Lopez R. Role of Sparc as a Prognostic Factor in Pancreatic Tumors. Ann Stem Cell Res Ther. 2018; 2(2): 1012.